Werewolf Therapeutics sells preclinical INDUCER, INDUKINE platforms to EMD Serono for USD 33 million

• Werewolf Therapeutics sold preclinical INDUCER platform technology to EMD Serono in an asset sale that closed Aug. 14, 2026.
• Deal also transfers parts of the INDUKINE platform, excluding the WTX-124 and WTX-330 clinical development programs.
• Consideration totals USD 33 million, including USD 28 million upfront and USD 5 million tied to completing the technology transfer.
• Exclusive license from EMD Serono preserves rights needed to continue developing WTX-124 and WTX-330.
• Non-compete restricts exploitation of certain transferred IP targeting the same tumor target as transferred compounds for 24 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-359185), on August 20, 2026, and is solely responsible for the information contained therein.